Filing identity and reporting period
The supplied filing is FibroGen, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022, not a filing for Kyntra Bio, Inc. Investors should verify the issuer before relying on this summary.
FibroGen is a biopharmaceutical company developing and commercializing therapies for anemia, fibrosis and cancer. Roxadustat is commercialized for CKD anemia in China and approved in several other markets; pamrevlumab is in Phase 3 development across multiple indications. Unless otherwise noted, amounts below are in U.S. dollars.
Financial results and position
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $60.8 million | $38.4 million; up 58% |
| Operating costs and expenses | $123.8 million | $108.9 million; up 14% |
| Operating loss | $63.0 million | $70.4 million loss |
| Net loss | $63.2 million; $0.68 per diluted share | $71.8 million; $0.78 per diluted share |
| Net cash used in operating activities | $8.5 million | $45.0 million |
- Revenue included $22.6 million of license revenue, $11.8 million of development and other revenue, $18.9 million of China product revenue and $7.6 million of drug product revenue. The $25.0 million Russian regulatory milestone from Astellas was recognized in the quarter; it was received in April.
- Research and development expense was $89.0 million, up 19%, primarily reflecting higher pamrevlumab manufacturing and clinical-trial costs. SG&A was $30.6 million, broadly flat year over year.
- Cash and cash equivalents were $185.9 million; short- and long-term investments totaled $335.7 million. Together, cash and investments were $521.6 million, down from $573.0 million at year-end 2021. Including $43.9 million of accounts receivable, these resources totaled $565.4 million.
- Current assets were $524.4 million versus current liabilities of $255.4 million. Total liabilities were $567.9 million. The balance sheet lists no conventional borrowings; it includes $96.9 million of operating lease liabilities and $17.4 million of product development obligations.
- Operating cash use was much lower than net loss, in part because of working-capital movements, including a $66.0 million increase in accrued and other liabilities. Investing activities provided $25.9 million, including investment maturities, and included a $35.0 million payment for an acquired in-process research and development asset.
- Accumulated deficit was $1.33 billion. No operating margin or gross margin was expressly reported in the supplied filing text.
Material changes versus the prior comparable period
- Revenue rose $22.4 million, chiefly due to the Russian milestone, higher China product revenue and Eluminex contract-manufacturing revenue; development revenue and drug product revenue declined.
- China product revenue increased 23% to $18.9 million. Management reported over 70% year-over-year growth in roxadustat unit volume in China, while the lower National Reimbursement Drug List price partly offset volume growth.
- R&D expense rose $14.3 million, mainly from pamrevlumab manufacturing and trials; roxadustat R&D expense fell to $16.5 million from $26.5 million.
- Net loss narrowed by $8.6 million, reflecting higher revenue partly offset by higher operating costs. Cash and investments declined by $51.4 million from December 31, 2021.
Outlook, commentary, risks and unusual items
- Management said existing cash, investments and receivables should fund anticipated cash needs for at least 12 months from the filing date, while also anticipating substantial additional funding needs thereafter and continued losses for the foreseeable future.
- FibroGen had not agreed with AstraZeneca on a path to fund further U.S. roxadustat development for CKD anemia and said it did not expect to receive most or all of the remaining U.S./Rest of World collaboration milestones. The FDA had issued a complete response letter for roxadustat in U.S. CKD anemia.
- Clinical expectations included MATTERHORN roxadustat topline data in the first half of 2023; ZEPHYRUS-1 pamrevlumab data in mid-2023; LELANTOS-1 data in the first half of 2023; and LAPIS overall-survival data in the first half of 2024. These are management expectations, not guarantees.
- Q1 included notable estimates and reclassifications for variable consideration on prior drug-product shipments: $60.8 million was reclassified from deferred revenue to accrued liabilities, including an estimated $45.5 million payable to Astellas in Q1 2023 and $11.2 million related to AstraZeneca. These estimates may change.
- Potential future cash commitments included $56.9 million of non-cancelable purchase obligations, $96.9 million of operating lease liabilities and up to approximately $704.1 million of development, regulatory and commercial milestone payments under certain licenses, generally contingent on future milestones.
- Risks include clinical and regulatory uncertainty, dependence on Astellas and AstraZeneca, manufacturing and supply constraints, China pricing and operating risks, and possible impacts of COVID-19 and the war in Ukraine on trials and operations.
- The company disclosed a securities class action and shareholder derivative litigation related to alleged statements about roxadustat trial data and FDA prospects, plus an SEC subpoena seeking documents concerning roxadustat pooled cardiovascular safety data. FibroGen said it was cooperating with the SEC and could not estimate any potential loss; no material legal accrual was recorded.
Important facts for investors to verify
- Confirm the issuer: the supplied document identifies FibroGen, Inc. (Nasdaq: FGEN), despite the request metadata naming Kyntra Bio, Inc.
- Review the status and outcome of the SEC investigation and securities and derivative litigation, and any resulting financial or business effects.
- Track the use of cash, working-capital movements and the company’s stated liquidity runway, including the extent to which China-held funds are available for use outside China.
- Monitor pamrevlumab trial timelines and results, and any changes in AstraZeneca’s funding or collaboration arrangements for roxadustat.
- Check subsequent disclosures for revisions to drug-product variable-consideration estimates, accrued liabilities and expected payments to Astellas or AstraZeneca.